HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

J Thorac Cardiovasc Surg 2009;137:302-303
© 2009 The American Association for Thoracic Surgery

Invited Commentary

Discussion

Dr Soichiro Kitamura (Osaka, Japan). I thank the Association for the privilege of discussing this fine article. I also thank Professor Angelini for allowing me to read the manuscript before the presentation. My compliments on a well—designed and well—conducted clinical study demonstrating again that OPCAB can offer good quality of surgical intervention in terms of 6 to 8 years' graft patency, survival and survival free from MACEs, and patients' HRQoL after surgical intervention in comparison with conventional on—pump CABG.

This article is certainly the extension of a previously published randomized clinical trial called the BHACAS 1 and 2 conducted almost 10 years ago, and today, the chief researchers again demonstrated that OPCAB, as compared with on-pump CABG, can yield a similar level of long-term survival and quality of life based on the similar long-term graft patency evaluated by using 16-array MDCTA.

Your group reported in 2002 and 2004 that OPCAB provided significant reduction in postoperative morbidity compared with that seen after conventional on-pump CABG, such as a 25% reduction in postoperative atrial fibrillation, a 31% reduction in blood transfusion, fewer chest infections, shorter . . . [Full Text of this Article]